X4 Pharmaceuticals
XFOR
49 hedge funds and large institutions have $98.4M invested in X4 Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 3 closing their positions.
257% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 7
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
14% more funds holding
Funds holding: 43 → 49 (+6)
0.04% more ownership
Funds ownership: 2.04% → 2.08% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $114M → $98.4M (-$15.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.3M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.16M |
| 3 |
State Street
Boston,
Massachusetts
|
+$806K |
| 4 |
Millennium Management
New York
|
+$488K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.06M |
| 2 |
First Eagle Investment Management
New York
|
-$536K |
| 3 |
Goldman Sachs
New York
|
-$227K |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$115K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$30K |
XFOR Hedge Fund Activity: Q3 2019 in Review
49 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2019, worth a combined $98.4M — down 14% from $114M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XFOR positions and 3 closed out — a net gain of 6 holders — while 25 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $3.3M. The largest seller was RA Capital Management, cutting an estimated $5.06M.
- 49 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2019, up from 43 in Q2 2019.
- Funds reported $98.4M of X4 Pharmaceuticals stock for Q3 2019, down 14% quarter-over-quarter.
- 9 funds opened new X4 Pharmaceuticals positions in Q3 2019 and 3 closed out, a net change of +6 holders.
- The largest X4 Pharmaceuticals buyer in Q3 2019 was BlackRock, an estimated $3.3M added.
- The largest X4 Pharmaceuticals seller in Q3 2019 was RA Capital Management, an estimated $5.06M sold.
Based on aggregated 13F filings for Q3 2019.